Published in JAMA · View the paper (DOI)
A Phase 3 clinical trial shows that lanadelumab injections significantly reduce the number of hereditary angioedema attacks, with improvements in quality of life. The treatment also outperforms placebo in reducing attack frequency and severity.
Coverage from 2 institutions